Research ExplorerPublicationsProstate-specific Membrane Antigen-radioguided Surgery Facil...

Prostate-specific Membrane Antigen-radioguided Surgery Facilitates Pelvic Lymph Node Dissection During Radical Prostatectomy for the Treatment of Locally Advanced Prostate Cancer with Regional Lymph Node Metastases

Standard

Prostate-specific Membrane Antigen-radioguided Surgery Facilitates Pelvic Lymph Node Dissection During Radical Prostatectomy for the Treatment of Locally Advanced Prostate Cancer with Regional Lymph Node Metastases. / Lunger, Lukas; Steinhelfer, Lisa; Korn, Philipp; Eiber, Matthias; Maurer, Tobias; Büchler, Jakob; Horn, Thomas; Gschwend, Jürgen E; Heck, Matthias M.

In: EUR UROL ONCOL, Vol. 6, No. 1, 02.2023, p. 95-98.

Research output: SCORING: Contribution to journal › Short publication › Research › peer-review

Harvard

Lunger, L, Steinhelfer, L, Korn, P, Eiber, M, Maurer, T, Büchler, J, Horn, T, Gschwend, JE & Heck, MM 2023, 'Prostate-specific Membrane Antigen-radioguided Surgery Facilitates Pelvic Lymph Node Dissection During Radical Prostatectomy for the Treatment of Locally Advanced Prostate Cancer with Regional Lymph Node Metastases', EUR UROL ONCOL, vol. 6, no. 1, pp. 95-98. https://doi.org/10.1016/j.euo.2022.12.001

APA

Lunger, L., Steinhelfer, L., Korn, P., Eiber, M., Maurer, T., Büchler, J., Horn, T., Gschwend, J. E., & Heck, M. M. (2023). Prostate-specific Membrane Antigen-radioguided Surgery Facilitates Pelvic Lymph Node Dissection During Radical Prostatectomy for the Treatment of Locally Advanced Prostate Cancer with Regional Lymph Node Metastases. EUR UROL ONCOL, 6(1), 95-98. https://doi.org/10.1016/j.euo.2022.12.001

Vancouver

Lunger L, Steinhelfer L, Korn P, Eiber M, Maurer T, Büchler J et al. Prostate-specific Membrane Antigen-radioguided Surgery Facilitates Pelvic Lymph Node Dissection During Radical Prostatectomy for the Treatment of Locally Advanced Prostate Cancer with Regional Lymph Node Metastases. EUR UROL ONCOL. 2023 Feb;6(1):95-98. https://doi.org/10.1016/j.euo.2022.12.001

Bibtex

@article{57a55f2522164a678cc6ce686482bfcf,
title = "Prostate-specific Membrane Antigen-radioguided Surgery Facilitates Pelvic Lymph Node Dissection During Radical Prostatectomy for the Treatment of Locally Advanced Prostate Cancer with Regional Lymph Node Metastases",
abstract = "Lymph node metastases (LNMs) are common in intermediate- to high-risk prostate cancer (PC) and may be missed during extended pelvic lymph node dissection (ePLND). Here we report on the use of prostate-specific membrane antigen (PSMA)-radioguided surgery (RGS) during open radical prostatectomy (RP) with ePLND to resect locoregional LNMs identified on preoperative PSMA positron emission tomography (PET). Preoperative PSMA PET showed 78 LNMs in 35 patients undergoing RP with ePLND and RGS between January 2018 and June 2020. In 14 patients (40%), LNMs were located outside the ePLND template. RGS achieved resection of PSMA-positive LNMs in 33/35 patients (94%). On univariable analysis, lower metastatic burden with up to two PSMA-positive LNMs on preoperative PET was associated with better postoperative outcomes. Limitations include the retrospective analysis and the small sample size. RGS facilitates resection of PSMA-positive LNs in patients treated with RP. Our data indicate a favorable treatment outcome in patients with low metastatic LN burden on preoperative PSMA PET. PATIENT SUMMARY: We investigated the use of radioactive guidance to remove lymph nodes affected by prostate cancer during surgical removal of the prostate. This approach can help to identify cancerous lymph nodes that might otherwise be missed and could lead to better survival outcomes.",
keywords = "Humans, Male, Lymph Node Excision/methods, Lymphatic Metastasis/pathology, Prostate/pathology, Prostatectomy, Prostatic Neoplasms/diagnostic imaging, Retrospective Studies, Surgery, Computer-Assisted/methods",
author = "Lukas Lunger and Lisa Steinhelfer and Philipp Korn and Matthias Eiber and Tobias Maurer and Jakob B{\"u}chler and Thomas Horn and Gschwend, {J{\"u}rgen E} and Heck, {Matthias M}",
note = "Copyright {\textcopyright} 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.",
year = "2023",
month = feb,
doi = "10.1016/j.euo.2022.12.001",
language = "English",
volume = "6",
pages = "95--98",
journal = "EUR UROL ONCOL",
issn = "2588-9311",
publisher = "Elsevier",
number = "1",

}

RIS

TY - JOUR

T1 - Prostate-specific Membrane Antigen-radioguided Surgery Facilitates Pelvic Lymph Node Dissection During Radical Prostatectomy for the Treatment of Locally Advanced Prostate Cancer with Regional Lymph Node Metastases

AU - Lunger, Lukas

AU - Steinhelfer, Lisa

AU - Korn, Philipp

AU - Eiber, Matthias

AU - Maurer, Tobias

AU - Büchler, Jakob

AU - Horn, Thomas

AU - Gschwend, Jürgen E

AU - Heck, Matthias M

N1 - Copyright © 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.

PY - 2023/2

Y1 - 2023/2

N2 - Lymph node metastases (LNMs) are common in intermediate- to high-risk prostate cancer (PC) and may be missed during extended pelvic lymph node dissection (ePLND). Here we report on the use of prostate-specific membrane antigen (PSMA)-radioguided surgery (RGS) during open radical prostatectomy (RP) with ePLND to resect locoregional LNMs identified on preoperative PSMA positron emission tomography (PET). Preoperative PSMA PET showed 78 LNMs in 35 patients undergoing RP with ePLND and RGS between January 2018 and June 2020. In 14 patients (40%), LNMs were located outside the ePLND template. RGS achieved resection of PSMA-positive LNMs in 33/35 patients (94%). On univariable analysis, lower metastatic burden with up to two PSMA-positive LNMs on preoperative PET was associated with better postoperative outcomes. Limitations include the retrospective analysis and the small sample size. RGS facilitates resection of PSMA-positive LNs in patients treated with RP. Our data indicate a favorable treatment outcome in patients with low metastatic LN burden on preoperative PSMA PET. PATIENT SUMMARY: We investigated the use of radioactive guidance to remove lymph nodes affected by prostate cancer during surgical removal of the prostate. This approach can help to identify cancerous lymph nodes that might otherwise be missed and could lead to better survival outcomes.

AB - Lymph node metastases (LNMs) are common in intermediate- to high-risk prostate cancer (PC) and may be missed during extended pelvic lymph node dissection (ePLND). Here we report on the use of prostate-specific membrane antigen (PSMA)-radioguided surgery (RGS) during open radical prostatectomy (RP) with ePLND to resect locoregional LNMs identified on preoperative PSMA positron emission tomography (PET). Preoperative PSMA PET showed 78 LNMs in 35 patients undergoing RP with ePLND and RGS between January 2018 and June 2020. In 14 patients (40%), LNMs were located outside the ePLND template. RGS achieved resection of PSMA-positive LNMs in 33/35 patients (94%). On univariable analysis, lower metastatic burden with up to two PSMA-positive LNMs on preoperative PET was associated with better postoperative outcomes. Limitations include the retrospective analysis and the small sample size. RGS facilitates resection of PSMA-positive LNs in patients treated with RP. Our data indicate a favorable treatment outcome in patients with low metastatic LN burden on preoperative PSMA PET. PATIENT SUMMARY: We investigated the use of radioactive guidance to remove lymph nodes affected by prostate cancer during surgical removal of the prostate. This approach can help to identify cancerous lymph nodes that might otherwise be missed and could lead to better survival outcomes.

KW - Humans

KW - Male

KW - Lymph Node Excision/methods

KW - Lymphatic Metastasis/pathology

KW - Prostate/pathology

KW - Prostatectomy

KW - Prostatic Neoplasms/diagnostic imaging

KW - Retrospective Studies

KW - Surgery, Computer-Assisted/methods

U2 - 10.1016/j.euo.2022.12.001

DO - 10.1016/j.euo.2022.12.001

M3 - Short publication

C2 - 36604297

VL - 6

SP - 95

EP - 98

JO - EUR UROL ONCOL

JF - EUR UROL ONCOL

SN - 2588-9311

IS - 1

ER -